Incannex Healthcare Limited American Depositary Shares
IXHLStock
$3.15−68.33%52W
Market Cap$38.65M
P/E—
Div yield—
Beta1.81
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-81.78%
Price vs S&P 500 (4W)-14.00%
VGM Score18.63
Market Capitalization$38.65M
Earnings Surprise History
Q3 26-11.23est. -0.94
Analyst Recommendations
Jul 2026
4.14
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IXHLIncannex Healthcare Limited American Depositary Shares | — | F | D | $3.15 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Incannex Healthcare is a clinical-stage pharmaceutical company developing cannabis-based therapeutics for Obstructive Sleep Apnea, Traumatic Brain Injury, Rheumatoid Arthritis, and various inflammatory conditions. The company holds an Australian license to import, export, and distribute medicinal cannabis and has commercialized a cannabinoid product line. Its research and development extends to both cannabis and psychedelic medicine applications.